| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/14/2004 | US20040204449 New isoquinoline compounds |
| 10/14/2004 | US20040204448 For inhibiting PDE4(phosphodiesteases) in a mammal; of modulating the production of TNF- alpha; inhibiting matrix metalloproteinases, for therapy of undesired angiogenesis; therapy of cancer |
| 10/14/2004 | US20040204446 Nitrogen compounds such as N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl) -acetamide, administered for prophylaxis arthritis, psoriasis, cardiovascular disorders, reperfusion injury or respiratory system disorders |
| 10/14/2004 | US20040204444 Combination of organic compounds |
| 10/14/2004 | US20040204443 Method for inducing pain relief using imidazo[1,2-a]pyridine derivatives |
| 10/14/2004 | US20040204442 In an insoluble matrix, such as shellac, high molecular weight polyethylene glycol polyvinyl alcohol, lactic acid - glycolic acid copolymer or sugars. Particularly preferred compounds are: enrofloxacin, danofloxacin and sarafloxacin |
| 10/14/2004 | US20040204441 Nasal delivery of apomorphine |
| 10/14/2004 | US20040204440 Composition, device, and method for treating sexual dysfunction via inhalation |
| 10/14/2004 | US20040204439 Composition, device, and method for treating sexual dysfunction via inhalation |
| 10/14/2004 | US20040204438 such as N-[4-(4-amino-1H-imidazol[4,5-c]quinolin-1-yl)butyl]-5-(dimethylamino)-naphthalenesulfonamide; for induction of biosynthesis of cytokines; immunomodulators; antineoplastic agents |
| 10/14/2004 | US20040204437 Substituted arylamine derivatives and methods of use |
| 10/14/2004 | US20040204436 Imidazonaphthyridines |
| 10/14/2004 | US20040204435 Alternating treatment with topoisomerase I and topoisomerase II inhibitors |
| 10/14/2004 | US20040204434 Compounds and methods for lowering the abuse potential and extending the duration of action of a drug |
| 10/14/2004 | US20040204433 High concentration of minoxidil; free from problems such as crystal precipitation and the like at low temperatures |
| 10/14/2004 | US20040204432 Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same |
| 10/14/2004 | US20040204430 Methods of treating sickle cell disease |
| 10/14/2004 | US20040204429 Reversible inhibitors of SAH hydrolase and uses thereof |
| 10/14/2004 | US20040204428 Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments |
| 10/14/2004 | US20040204426 4-Imidazolin-2-one compounds |
| 10/14/2004 | US20040204425 Sodium channel blockers |
| 10/14/2004 | US20040204424 Such as 4-(4-hydroxyphenyl)butylamidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride; time-release agents; for therapy of chronic bronchitis, emphysema, cystic fibrosis, and eye disorders |
| 10/14/2004 | US20040204420 Compounds for modulating RNA interference |
| 10/14/2004 | US20040204419 For therapy of cancer |
| 10/14/2004 | US20040204418 For prophylaxis and therapy of asthma, chronic obstructive pulmonary disease, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilia, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease |
| 10/14/2004 | US20040204417 For therapy of cancer |
| 10/14/2004 | US20040204416 Pharmaceutical composition for the treatment of CNS and other disorders |
| 10/14/2004 | US20040204415 Pyrrolo[1,2-B]pyridazine compounds and their uses |
| 10/14/2004 | US20040204414 Pyrrolo[1,2-B]pyridazine compounds and their uses |
| 10/14/2004 | US20040204412 Useful as anticoagulants in therapy and prophylaxis of cardiovascular diseases, as anti-inflammatory agents, and as metastasis inhibitors in therapy of cancer |
| 10/14/2004 | US20040204411 Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| 10/14/2004 | US20040204408 Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity |
| 10/14/2004 | US20040204404 Human N-type calcium channel blockers |
| 10/14/2004 | US20040204403 Pharmaceutical composition comprising ibuprofen and prochlorperazine |
| 10/14/2004 | US20040204399 Aerosolized decongestants for the treatment of sinusitis |
| 10/14/2004 | US20040204398 Acylated piperazine derivatives as melanocortin-4 receptor agonists |
| 10/14/2004 | US20040204396 Spirocyclopropyl amides and acids and their therapeutic applications |
| 10/14/2004 | US20040204393 Aromatase inhibition to enhance assisted reproduction |
| 10/14/2004 | US20040204392 use of trilostane or a 3-enol C1-4 alkanoate ester thereof; treatment of Cushing's syndrome in humans and veterinary animals |
| 10/14/2004 | US20040204391 Applying onto healed wound a composition comprising a fluid, film-forming carrier, and subsequently hardening the carrier into a tangible membrane juxtaposed to the healed wound thereby reducing scarring or improving the appearance thereof |
| 10/14/2004 | US20040204390 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist |
| 10/14/2004 | US20040204389 Anti-HIV agents with dual sites of action |
| 10/14/2004 | US20040204388 incubating SV2 protein or fragment with levetiracetam or an analog or derivative thereof and a potential binding partner and determining if the potential binding partner modulates the binding of levetiracetam to the SV2 protein |
| 10/14/2004 | US20040204387 administering to subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof; for treating or preventing condition of central or peripheral nervous system or systemic organ associated with a disorder in protein folding or aggregation, or amyloid formation |
| 10/14/2004 | US20040204386 for uses such as inhibiting the activity of lysophosphatidic acid acyltransferase beta and/or inhibiting the proliferation of a cell (e.g., tumor cell) |
| 10/14/2004 | US20040204385 increasing the copper levels in an animal by the administration of a composition containing copper dextran in a dose in a manner selected from parenterally; intramuscularly; and a combination thereof |
| 10/14/2004 | US20040204384 Polymer comprises an effective quantity of disaccharide units each composed of an N-acetyl-D-glucosamine structure molecule bonded by an O-glycoside beta 1,4 bond with a glucuronic acid structure molecule, e.g., hyaluronic acid; treatment of acute lymphoblastic leukaemias |
| 10/14/2004 | US20040204383 administering compound GW9662 that inhibits signaling through peroxisome proliferator-activated receptor gamma; assigns a pivotal role to lysophosphatidic acid in atherogenesis |
| 10/14/2004 | US20040204382 ephedra- and artificial stimulant-free energy promoting composition can comprise effective amounts of a magnesium amino acid chelate, a B vitamin, a pyruvate salt, and rhodiola |
| 10/14/2004 | US20040204379 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| 10/14/2004 | US20040204378 polyazaalkane, polyaminoalkane, or mixed poly(aza/amino)alkane, any carbon atom of which may be hydroxyl, amino, or oxo substituted, and wherein said inhibitor contains at least two nitrogen atoms that are bonded to a lipophilic group; for treating infections in plants or animals |
| 10/14/2004 | US20040204375 Gene delivery compounds |
| 10/14/2004 | US20040204371 for ADMINISTERING TO THE BLACK PATIENT FOR IMPROVING OXYGEN CONSUMPTION TO PREVENT HEART FAILURE, A HYDRALAZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT AND AT LEAST ONE ISOBORIDE DINITRATE OR ISOBORIDE MONONITRATE |
| 10/14/2004 | US20040204366 one effecting opioid analgesia and one effecting local anesthesia, in amounts sufficient to potentiate an antinociceptive response when both compounds are topically administered in a physiologically acceptable topical excipient |
| 10/14/2004 | US20040204356 Treatment of diabetes |
| 10/14/2004 | US20040204355 alpha 7 receptor is the alpha -bungarotoxin sensitive receptor that influences the release of proinflammatory cytokines from macrophages |
| 10/14/2004 | US20040204354 An artificial LDL particle containing an outer phospholipid monolayer(contains at least one apolipoprotein) and a solid lipid core which contains at least one therapeutic agent |
| 10/14/2004 | US20040204347 administering an effective amount of an inhibitor of the interaction of glutamate with the alpha -amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptor complex to treat demyelinating disorders |
| 10/14/2004 | US20040204345 Using recombinant zinc finger proteins; use in human therapeutic applications such as cancer therapy and altering plant phenotypes, including disease resistance, fruit ripening |
| 10/14/2004 | US20040204344 bifunctional molecules containing at least one metal-chelating group associated with at least one amyloid-binding group e.g a benzothiazole derivative; for treating pathophysiological condition selected from Alzheimer's disease, Down's syndrome, Lewy body dementia, Guam Parkinson-Dementia, head trauma |
| 10/14/2004 | US20040204341 Nr2b receptor antagonists for the treatment or prevention of migraines |
| 10/14/2004 | US20040204339 Anticancer agents; administering dosage of Dna methylation antagonist such as decitabine and enzyme inhibitor |
| 10/14/2004 | US20040203157 Transfroming arabidopsis with expression vector coding genes associated with heat, freeze, salt and drought resistance; using ribonucleoproteins to control effivient gene transcription in plants; bioreactors |
| 10/14/2004 | US20040203145 single stranded small interfering RNA strands for treatment of autoimmune diseases; kits |
| 10/14/2004 | US20040203121 Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids |
| 10/14/2004 | US20040203111 UDP-N-acetylglucosamine: galactose-B1,3-N-acetylgalactosamine-a-R/ (GlcNAc to GalNAc) B1-6 N- acetylglucosaminyltransferase, C2GnT3 |
| 10/14/2004 | US20040203099 Conjugate of a transport protein and a protein for modulation of notch signalling |
| 10/14/2004 | US20040203098 Compounds and methods for modulating activation of NF-kappaB |
| 10/14/2004 | US20040203092 UDP-N-acetylglucosamine:galactose-beta1,3-N-acetylgalactosamine-alpha-R/ (GlcNAc to GalNAc) beta1-6 N-acetylglucosaminyltransferase, C2GnT3 |
| 10/14/2004 | US20040203087 screening gene expression inhibition via incubating mrna, determining expression in presence of test compound, then comparing levels; gene knockout |
| 10/14/2004 | US20040202740 Annatto extract compositions, including geranyl geraniols and methods of use |
| 10/14/2004 | US20040202739 Compositions and methods for treating female sexual response |
| 10/14/2004 | US20040202736 Method of ameliorating side-effects of SERMs |
| 10/14/2004 | US20040202735 Delivering vanilloid receptor agonist to blood vessel disruption site; effective even for major surgical incisions and in presence of anticoagulants |
| 10/14/2004 | US20040202734 Method for preparing nicotianamine or nicotianamine-containing product |
| 10/14/2004 | US20040202732 orally administered synergistic weight loss combination of epigallocatechin gallate and conjugated linoleic acid |
| 10/14/2004 | US20040202731 Rosmarinic acid composition |
| 10/14/2004 | US20040202730 for treating heart conditions containing borneol, rosmarinic acid and ginsenoside Rg1 or ginsenoside Rb1; paste, resin, oil, or a powder suitable for use in a fast dissolve tablet |
| 10/14/2004 | US20040202729 for delivering sulfur containing compounds to skin and absorbing irritants in the skin; high sorption base is employed which comprises non-swelling clay, gum, swelling clay, silicon and combinations thereof; treatment of skin disorders |
| 10/14/2004 | US20040202727 Dysfunctional satiety center syndrome and method of treatment therefor |
| 10/14/2004 | US20040202726 liquid carrier comprising: water; potassium chloride; and a penetrant enhancer for enhancing the penetration of the potassium chloride into the skin. |
| 10/14/2004 | US20040202722 Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof |
| 10/14/2004 | US20040202718 compressible controlled release core, swellable polymers one of which is anionic, and an excipient(s) that improves compressibility; an immediate release composition comprising long-acting sulfonyl urea (glimepiride) and controlled release composition comprising biguanide (metformin) |
| 10/14/2004 | US20040202717 Abuse-resistant oral dosage forms and method of use thereof |
| 10/14/2004 | US20040202716 Composition |
| 10/14/2004 | US20040202715 Intraoral quickly disintegrating tablets |
| 10/14/2004 | US20040202714 Oral pharmaceutical composition |
| 10/14/2004 | US20040202713 Means and method for hormonal contraception |
| 10/14/2004 | US20040202712 Emulsion vehicle for poorly soluble drugs |
| 10/14/2004 | US20040202711 Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia |
| 10/14/2004 | US20040202707 self-adhesive matrix based on polysiloxanes and containing capsaicin contains liquid microreservoir droplets of an amphiphilic solvent, in which the capsaicin is dissolved |
| 10/14/2004 | US20040202705 including as a permeation enhancer fatty acids, fatty acid esters, fatty alcohols, amides, pyrrolidones, glycerol triesters, and/or terpenes and their salts; provides a huperzine blood plasma level of 0.1 - 30 mg/ml |
| 10/14/2004 | US20040202702 Method and composition for the treatment of scars |
| 10/14/2004 | US20040202700 Method for making infection preventive fabric articles suitable for use in ono-invasive biomedical and protective topical applications |
| 10/14/2004 | US20040202693 Pharmaceutical compositions releasing their active agents from a buccal or sublingual location to overcome an absorption window problem |
| 10/14/2004 | US20040202687 Ciprofloxacin formulations and methods of making and using the same |
| 10/14/2004 | US20040202681 Process for preparing pharmaceutical formulations using supercritical fluids |
| 10/14/2004 | US20040202677 topically applying a hydroglycolic fluid extract of Palmaria palmata, Laminaria digitata extract, mannitol, and a carrier while administering an amount of a fat reduction oral composition of synephrine, a methylxanthine such as caffeine or theobromine, chromium source (chromium picolinate), and a carrier |
| 10/14/2004 | US20040202656 Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders |
| 10/14/2004 | US20040202649 Identification of the MECA-79 antigen and related methods of treating L-selectin-mediated conditions |